Cargando…

Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study

BACKGROUND: In 2019, British Columbia’s public drug plan, PharmaCare, was the first in Canada to implement a nonmedical switching policy from originator infliximab to its biosimilar, for patients with inflammatory arthritis or psoriasis. We aimed to detect signals of impact on health services utiliz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fisher, Anat, Kim, Jason D., Dormuth, Colin R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Impact Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259384/ https://www.ncbi.nlm.nih.gov/pubmed/35168933 http://dx.doi.org/10.9778/cmajo.20200319

Ejemplares similares

Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study
por: Fisher, Anat, et al.
Publicado: (2023)

Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia
por: Fisher, Anat, et al.
Publicado: (2022)

Trends in antihypertensive drug utilization in British Columbia, 2004–2019: a descriptive study
por: Kim, Jason D., et al.
Publicado: (2023)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Policy‐induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia
por: Fisher, Anat, et al.
Publicado: (2019)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis
por: Glintborg, Bente, et al.
Publicado: (2018)

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
por: Fleischmann, Roy, et al.
Publicado: (2020)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada
por: Carney, Greg, et al.
Publicado: (2022)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Patient perspectives on the British Columbia Biosimilars Initiative: a qualitative descriptive study
por: Chew, Caitlin, et al.
Publicado: (2021)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial
por: Goll, G. L., et al.
Publicado: (2019)

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2018)

Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
por: Martínez-Feito, Ana, et al.
Publicado: (2020)

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
por: Petit, Juliette, et al.
Publicado: (2021)

Outcomes associated with hospital admissions for accidental opioid overdose in British Columbia: a retrospective cohort study
por: Morrow, Richard L, et al.
Publicado: (2019)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease
por: Huoponen, Saara, et al.
Publicado: (2020)

Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up
por: Kurizky, Patricia Shu, et al.
Publicado: (2019)

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product
por: Abdalla, Abuelmagd, et al.
Publicado: (2017)

Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage
por: Cadarette, S. M., et al.
Publicado: (2011)

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
por: Peng, Kuan, et al.
Publicado: (2023)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

In the Wake of a Pandemic: Revisiting School Approaches to Nonmedical Exemptions to Mandatory Vaccination in the US
por: Paquette, Erin Talati
Publicado: (2021)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease
por: Kashima, Shin, et al.
Publicado: (2022)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
por: Massimi, Davide, et al.
Publicado: (2021)

Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
por: Yazici, Yusuf, et al.
Publicado: (2018)

Highlight: British Columbia
Publicado: (2005)

Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis
por: Glintborg, Bente, et al.
Publicado: (2019)

Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
por: Fischer, Sarah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ddeih8qdqo38vdt13tsh8e27o6